Li Sun
First Affiliated Hospital of Wenzhou Medical University · Guizhou Provincial Peoples Hospital · Children's Hospital of Fudan University
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Li Sun as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 04:20 UTC. Open this list on ClinicalTrials.gov
- Early Ph1NCT06420154 · The Safety and Efficacy of Anti-CD19 CAR-T Cells in Patients With Relapsed/Refractory Autoimmune DiseasesFirst Affiliated Hospital of Wenzhou Medical University · not yet recruiting · Systemic Lupus Erythematosus (SLE), Sjogren's Syndrome, Systemic Sclerosis · principal investigator
- Ph2NCT06180889 · Factor XI inhibiTion for the Prevention of Venous Thromboembolism in Patients Undergoing Total Knee ArthroplastySuzhou Alphamab Co., Ltd. · active not recruiting · Knee Arthroplasty, Total · principal investigator
- N/ANCT03647852 · Clinical Study on Strategy for Refractory Henoch-Schönlein PurpuraChildren's Hospital of Fudan University · recruiting · Henoch-Schönlein Purpura · principal investigator
- N/ANCT02961413 · A Prospective Cohort Study on Drug-induced Liver Injury in China(DILI-P)Drug Induced Liver Disease Study Group · recruiting · Drug-induced Liver Injury · principal investigator
- Ph3NCT01469221 · Efficacy and Safety Study of Apaziquone vs. Placebo in Patients With Non-Muscle Invasive Bladder Cancer (NMIBC)Spectrum Pharmaceuticals, Inc · terminated · Bladder Cancer · study director
- Ph3NCT01410565 · Efficacy and Safety of Multi-Instillations of Apaziquone in Patients With Non-Muscle Invasive Bladder CancerSpectrum Pharmaceuticals, Inc · terminated · Bladder Cancer · study director
- Ph2NCT00005874 · Nitrocamptothecin in Treating Patients With Soft Tissue SarcomasAstex Pharmaceuticals, Inc. · completed · Gastrointestinal Stromal Tumor, Sarcoma, Small Intestine Cancer · study chair
- Ph2NCT00005875 · Nitrocamptothecin in Treating Patients With Metastatic MelanomaAstex Pharmaceuticals, Inc. · completed · Melanoma (Skin) · study chair
- Ph2NCT00005873 · Nitrocamptothecin in Treating Patients With Locally Recurrent or Metastatic Breast CancerAstex Pharmaceuticals, Inc. · completed · Breast Cancer · study chair
- Ph2NCT00005872 · Nitrocamptothecin in Treating Patients With Recurrent Non-small Cell Lung CancerAstex Pharmaceuticals, Inc. · completed · Lung Cancer · study chair
- Ph2NCT00005877 · Nitrocamptothecin in Treating Patients With Advanced or Recurrent Colorectal CancerAstex Pharmaceuticals, Inc. · unknown · Colorectal Cancer · study chair
- Ph2NCT00005876 · Nitrocamptothecin in Treating Patients With Locally Advanced or Metastatic Stomach Cancer That Cannot Be Removed During SurgeryAstex Pharmaceuticals, Inc. · unknown · Esophageal Cancer, Gastric Cancer · study chair
Grants
NIH projects from RePORTER, fetched 2026-11-12 04:20 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 64 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Bioinformatics Core for Single Cell and Spatial TranscriptomicsU19AI189176 · NIAID · BOSTON CHILDREN'S HOSPITAL · fiscal years 2025 to 2026 · $454,001 awarded in 2026Same name and institution; not confirmed by an ID
- COG NCORP Research BaseUG1CA189955 · NCI · CHILDREN'S HOSP OF PHILADELPHIA · fiscal years 2014 to 2018 · $3,037,489 awarded in 2018Same name and institution; not confirmed by an ID
- DEVELOPMENT OF IPDR AS A RADIOSENSITIZING DRUGR44CA076835 · NCI · SPARTA PHARMACEUTICALS, INC. · fiscal years 2000 · $193,157 awarded in 2000Same name and institution; not confirmed by an ID
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 04:20 UTC. The ranking covers the 200 most relevant of 782 PubMed records, and a shared surname and initials can bring in a namesake. All 782 on PubMed
- An inactivated enterovirus 71 vaccine in healthy children.N Engl J Med · 2014329 citationsRCR 12.0
- Highly functional virus-specific cellular immune response in asymptomatic SARS-CoV-2 infection.J Exp Med · 2021267 citationsRCR 11.9
- Tarlatamab in Small-Cell Lung Cancer after Platinum-Based Chemotherapy.N Engl J Med · 2025239 citationsRCR 48.2
- 233 citationsRCR 19.9
- Effect of Dasatinib vs Imatinib in the Treatment of Pediatric Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Randomized Clinical Trial.JAMA Oncol · 2020202 citationsRCR 9.1
- Vorinostat or placebo in combination with bortezomib in patients with multiple myeloma (VANTAGE 088): a multicentre, randomised, double-blind study.Lancet Oncol · 2013191 citationsRCR 4.7
- Toripalimab combined with lenvatinib and GEMOX is a promising regimen as first-line treatment for advanced intrahepatic cholangiocarcinoma: a single-center, single-arm, phase 2 study.Signal Transduct Target Ther · 2023156 citationsRCR 12.7
- 131 citationsRCR 16.3
- 116 citationsRCR 6.6
- Fuzheng Jiedu Xiaoji formulation inhibits hepatocellular carcinoma progression in patients by targeting the AKT/CyclinD1/p21/p27 pathway.Phytomedicine · 2021100 citationsRCR 6.9